

2026 STARS MEASURES

PART C MEASURES (HEDIS, NCQA)

Measure	MEASURE DESCRIPTION	WT.	AGE	DATE RANGE
CBP	Members diagnosed with hypertension (HTN) whose blood pressure (BP) was controlled (<140/90 mm Hg)	3.0	18 - 85	Jan 1, 2026 to Dec 31, 2026 (yearly)
BCS-E	Breast Cancer Screening (Mammography or Exclusion)	1.0	40-74	Oct 1, 2024 to Dec 31, 2026 (27 months)
COL-E	iFOBT/gFOBT- Fecal occult blood test	1.0	45-75	Jan 1, 2026 to Dec 31, 2026 (yearly)
	Flexible sigmoidoscopy CT Colonography			Jan 1, 2022 to Dec 31, 2026 (5 years)
	Colonoscopy			Jan 1, 2017 to Dec 31, 2026 (10 years)
	FIT-DNA Test			Jan 1, 2024 to Dec 31, 2026 (3 years)
OMW	The percentage of women who suffered a fracture and who had either a bone mineral density (BMD) test OR prescription for a drug to treat osteoporosis in the 180 days (6 months) after the fracture.	1.0	67-85	Jul 1, 2025 to Jun 30, 2026 (yearly)
TRC-MRP*	Percentage of members with an acute or non-acute inpatient discharge on or between Jan. 1-Dec. 1 of the measurement year with medication reconciliation documented on the date of the discharge through 30 days after the discharge (31 days total).	0.25	≥18	Jan 1, 2026 to Dec 1, 2026 (yearly)
TRC-PE*	Percentage of members with acute or non-acute inpatient discharges on or between Jan. 1–Dec. 1 of the measurement year with engagement documented within 30 days of the discharge. Do not include patient engagement that happens on the day of discharge.	0.25	≥18	Jan 1, 2026 to Dec 1, 2026 (yearly)
SPC	Patients diagnosed with ASCVD who were dispensed high-intensity or moderate-intensity statin medications and remained on these medications for at least 80% of the treatment period	0.0	21-75	Jan 1, 2026 to Dec 31, 2026 (yearly)
GSD	Members with Type 1 or Type 2 diabetes whose most recent glycemic status (measured by hemoglobin A1c [HbA1c] or glucose management indicator [GMI]) was either below 8.0% or above 9.0% during the measurement year. (Good control is defined as <8%)	3.0	18-75	Jan 1, 2026 to Dec 31, 2026 (yearly)
EED**	Percentage of members with diabetes who had an eye exam (retinal) to check for damage from diabetes during the measurement year or had a negative eye exam in prior year.	1.0	18-75	Jan 1, 2026 to Dec 31, 2026 (yearly)
KED	The percentage of members 18-85 years of age with diabetes (type 1 and type 2) who received a kidney health evaluation, defined by an estimated glomerular filtration rate (eGFR) AND a urine albumin-creatinine ratio (uACR), during the measurement year.	1.0	18-85	Jan 1, 2026 to Dec 31, 2026 (yearly)
PCR	The risk-adjusted ratio of observed-to-expected unplanned acute readmissions (inpatient and observation stays) for any diagnosis within 30 days of an acute hospitalization (inpatient and observation stays) for members ages 18 and older. A lower rate indicates a better score for this measure.	3.0	≥18	Jan 1, 2026 to Dec 31, 2026 (yearly)
FMC	The percentage of emergency department (ED) visits for members 18 years of age and older who have multiple high-risk chronic conditions who had a follow-up service within 7 days of the ED visit.	0.0	≥18	Jan 1, 2026 to Dec 31, 2026 (yearly)
CARE FOR OLDER ADULTS (COA) SNP MEMBERS 66 AND OLDER				
COA FSA	Functional Status Assessment during measurement year	1.0	SNP ≥ 66	Jan 1, 2026 to Dec 31, 2026 (yearly)
COA MED REV	Medication review w/ presence of a medication list in the medical record (needs to include both to close gap)	1.0	SNP ≥ 66	Jan 1, 2026 to Dec 31, 2026 (yearly)

PART D MEASURES (PQA)

COB	Percentage of Medicare Part D beneficiaries ages 18 and older with concurrent use of prescription opioids and benzodiazepines. Lower Rates represent better performance	0.0	≥18	Jan 1, 2026 to Dec 31, 2026 (yearly)
MED ADH DM	Taking oral diabetes medication(s) as directed. Plan members who take insulin are not included in the measure	3.0	≥18	Jan 1, 2026 to Dec 31, 2026 (yearly)
MED ADH HTN	Taking blood pressure ACE or ARB medication(s) as directed	3.0	≥18	Jan 1, 2026 to Dec 31, 2026 (yearly)
MED ADH CHOL	Taking cholesterol statin medication(s) as directed	3.0	≥18	Jan 1, 2026 to Dec 31, 2026 (yearly)
Poly-ACH	The percentage of Medicare Part D beneficiaries ages 65 and older with concurrent use of 2 or more unique (different active ingredient) anticholinergic (ACH) medications. Lower Rates represent better performance.	0.0	≥ 65	Jan 1, 2026 to Dec 31, 2026 (yearly)
SUPD	Diabetic patients with two fills of diabetes prescription claims need to be dispensed statin medication.	1.0	40-75	Jan 1, 2026 to Dec 31, 2026 (yearly)

(*) This measure is collected as an indicator in the Transitions of Care (TRC)

(**) EED will move to admin only

(Part D Measures) No reporting required from providers. The health plan evaluates prescription claims data for these measures.

(MED ADH) Members are compliant when prescriptions are filled more than 80% of the time; start date begins with first fill date once the second fill is obtained.